BioPoint Inc

Takeda Pharmaceutical Company reported that its AI-designed psoriasis pill outperformed Sotyktu in a head-to-head trial. The results highlight the growing potential of AI-driven drug development. https://www.biospace.com/drug-development/takedas-ai-designed-pill-bests-bms-sotyktu-in-head-to-head-psoriasis-trial

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.

Revolution Medicines and Tango Therapeutics reported a 92% response rate in a pancreatic cancer combination study. The results highlight strong potential for the experimental treatment. https://www.biospace.com/drug-development/wow-revmed-and-tangos-pancreatic-cancer-combo-hit-92-response

‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.

Massachusetts life sciences employment declined in 2025, ending a 14-year streak of industry job growth. The slowdown reflects broader challenges facing the biotech sector. https://www.biospace.com/job-trends/massachusetts-life-sciences-employment-dipped-last-year-following-14-years-of-growth-report

Massachusetts’ life sciences employment dipped last year following 14 years of growth: report Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

Travere Therapeutics signed a deal worth up to $1.1B to expand its rare kidney disease portfolio. The agreement strengthens its presence in the rare disease market. https://www.biospace.com/deals/travere-beefs-up-rare-kidney-disease-portfolio-with-up-to-1-1b-china-deal

Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.